
    
      Prostate cancer is the most common non-cutaneous cancer diagnosed in men in the United
      States. The majority of deaths occur in men with androgen-independent prostate cancer [AIPC].
      Although 80% of men with advanced cancer will initially respond to androgen ablation with
      disease regression or stabilization, their malignancies become resistant to such therapy.
    
  